
    
      This is a randomized, open-label phase III study. The treatment was compare the efficacy and
      safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX)
      treating stage â…¢ gastric cancer as adjuvant setting. The primary endpoint is the 3-year
      diseases-free survival (DFS) rate. The secondary endpoints are the overall survival (OS) and
      safety.
    
  